Novartis and NHS England have forged a pact to accelerate the access of its new cholesterol-lowering drug inclisiran for primary prevention of cardiovascular disease. Health Secretary Matt Hancock ...
At its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce levels with just two injections a year. The FDA has approved the drug under the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback